Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)
Status:
Not yet recruiting
Trial end date:
2022-10-30
Target enrollment:
Participant gender:
Summary
This study is a phase III clinical study to assess the efficacy and safety of Revefenacin
inhalation solution 175 mcg administered once daily via nebulization for 12 weeks compared to
placebo in a population of Chinese subjects with moderate to very severe COPD.